Cell Therapy Proteins

MHC Complexes, CAR-T Targets, VLPs, Cytokines, and Laminin 521

Products

Overview

Cell therapy includes immunocellular therapy and stem cell therapy. It utilizes cells from the patient or a donor, which, after being cultured, expanded, activated, or genetically edited ex vivo, are reinfused into the patient. This stimulates or enhances the body’s immune function, thereby achieving a method of controlling diseases. Based on different mechanisms of action, typical types of cell therapy include CAR-T, TILs, TCR-T, CAR-NK, etc.

Figure 1. General Process of Immunocellular Therapy [1][2].

KACTUS Proteins for Cell Therapy Development

Supporting you from discovery through manufacturing.

Immunization Proteins for Drug Discovery

During the drug discovery phase of cell therapy, especially for reprogrammed cell therapeutic drugs, such as immune cells loaded with CAR (Chimeric Antigen Receptor), it is often necessary to obtain the correct scFv (Single-chain Variable Fragment) sequence through immunization with relevant target antigen proteins. This enables the drug product cells to accurately identify tumor cells expressing antigens. KACTUS offers a series of high-quality target antigen protein options for customers to choose from.

MHC Complexes

Intracellular antigen targets are a major direction in cell therapy. Peptide segments, resulted from the degradation of intracellular antigens, form complexes with MHC and are presented on the cell surface for TCR recognition. Targeting MHC peptide complexes can achieve the killing of tumor cells.

KACTUS peptide-MHC complexes cover a variety of popular targets, and include monomers, tetramers, fluorescently-labeled tetramers, and other forms, which can be used for immunization or screening research in the development of T-cell therapeutic drugs. KACTUS also offers custom MHC expression, custom TCR expression, and peptide-ready MHCs to build your own peptide-MHC in house.

Figure 2. Through ELISA and SPR experiments, we have verified that the monomer of HLA-A*02:01&B2M&AFP (FMNKFIYEI) complex can bind separately with Anti-AFP (HLA-A*02:01) Antibody and HLA-A*02:01&B2M&AFP TCR. The EC50 and affinity constant are 7.6 ng/mL and 0.923 μM, respectively.

Figure 3. (Left) Through ELISA validation, it has been confirmed that gp100 TCR & CD3 scfv fusion protein can bind to the monomer of HLA-A*02:01&B2M&GP100 (YLEPGPVTA) complex, with an EC50 of 11.8 ng/mL. (Right) In the SPR analysis, gp100 TCR & CD3 scfv fusion protein can bind to the tetramer of the HLA-A*02:01&B2M&GP100 (YLEPGPVTA) complex, with an affinity constant of 0.196 nM.

CAR-T Target Proteins

KACTUS’ high-activity CAR-T target proteins can be applied during the early animal immunization stage for antibody discovery.

Figure 4. CAR-T target proteins, Human CD19 and Human CD7 proteins, can both bind well with the corresponding antibodies.

VLP SuperAntigens

Cell therapy targets include multiple transmembrane proteins (such as the GPCR family) and some targets for which it is difficult to obtain ideal antibody sequences through direct immunization. Our virus-like particle (VLP) display technology can maintain the correct conformation of multiple transmembrane proteins while enhancing the immunogenicity of the protein. In addition, the VLP framework can be designed specifically for your antigen with our custom VLP services.

Proteins for Cell Therapy Production & Analysis

Production preparation is a crucial step to obtain immunocellular drugs and is also key to the successful registration of cell drugs. KACTUS provides high-activity cytokines for cell culture and cell matrix proteins required for stem cell differentiation.

Laminin 521 for Stem Cell Culture

KACTUS offers recombinant Laminin 521 at research-grade, preclinical-grade, and cell therapy-grade. Laminin 521 is an important matrix adhesion protein for maintaining stem cells in culture.

Figure 5. The cell culture matrix protein Laminin 521 can effectively promote the growth of human iPSCs.

Figure 6. The cell culture matrix protein Laminin 521 can maintain the differentiation potential of stem cells.

Cytokines for Cell Culture

Cell culture is a necessary step for the preparation of cell-based therapies. Immunotherapy involving T cells, NK cells, and stem-cell derived immunocytes requires the preparation of stem cells such as ESCs, MSCs, and iPSCs. KACTUS offers a variety of cytokine products for cell culture.

Figure 7. (Left) We demonstrate via cell analysis that our Human IL-15 can promote the proliferation of MO7e cells, with an ED50 of 1-2 ng/mL. (Right) Through cellular level analysis, Human Wnt Surrogate can induce the activity of the Topflash reporter gene in HEK293 cells, with an ED50 of 5.2 ng/mL.

Figure 8. (Left) Via cellular-level analysis, we demonstrate that in the presence of Wnt Surrogate (5 ng/mL), Human R-spondin 1 Protein induced the activity of the Topflash reporter gene in HEK293 cells, with an ED50 between 1.0-10.0 ng/mL. (Right) Via cellular-level analysis, we validated that Human IL-7 Protein can promote the proliferation of 2E8 cells, with an ED50 value between 0.1-0.5 ng/mL.

Fluorescent or Biotinylated Proteins For Antibody Screening & Cell Therapy Analysis

Proteins labeled with fluorescence or biotin can be used for various detection processes in the production and quality inspection of therapeutic cells, such as antibody screening (such as scFv, etc.), CAR affinity research, CAR-T positivity rate detection, TCR screening or detection, and Blocking Assay, etc. KACTUS provides high-quality proteins labeled with different fluorescent markers like FITC, PE, as well as biotin-labeled proteins, to meet the needs of various analytical scenarios including cellular level analyses.

Figure 9. Through cellular-level flow cytometry detection, we demonstrated that FITC-Compatible Human CD19 protein can specifically bind with Anti-CD19-CAR T cells.

Figure 10. Through cellular-level flow cytometry detection, we demonstrated the fluorescently labeled HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) tetramer complex can bind well with HLA-A*02:01&B2M&NY-ESO-1 TCR cells.

GMP-Grade CRISPR Enzymes for Cellular Gene Editing

Allogeneic off-the-shelf cellular therapy products, such as UCAR-T, require the use of gene-editing technologies to knock out genes related to immune rejection reactions on donor T cells, to avoid inducing immune rejection reactions like GvHD and HvGR.

KACTUS offers GMP-Grade CRISPR Cas9 and GMP-Ready Cas12a for genetic modification of cells, including UCAR-T cell therapy. Regulatory support documentation is available. Moreover, our GMP-Grade Cas9 has been registered with the FDA Drug Master files (DMF #036578). Additionally, check out our CRISPR Cas9 ELISA kit to detect residual Cas9 nuclease in your cell product.

Figure 11. (Left) Cas9 Nuclease is used for gene knockout in 293T cells, Jurkat cells, and T cells, and its gene knockout efficiency in various cell types is comparable to that of leading suppliers. (Right) Cas9 Nuclease In Vitro DNA Cleavage Experiment. The in vitro cleavage efficiency of Cas9 nuclease is equivalent across all three batches.

Cas9 ELISA Kit

Quantitatively detect the residue of Cas9 nuclease in extracellular or intracellular spaces of gene-edited cell drugs before reinfusion into the human body. The detection range of our Cas9 ELISA kit is 0.25 ng/mL – 16 ng/mL, with a sensitivity that can reach 0.125 ng/mL.

Figure 12. Polynomial fitting of the Cas9 ELISA standard curve. The R² is 0.9997.

GMP-Grade MaxNuclease for DNA/RNA Degradation

In gene therapy, MaxNuclease principally serves to eliminate contaminants like host DNA and plasmid DNA present during the pharmaceutical production process. This GMP-grade nuclease is produced within a facility maintaining stringent GMP-Grade production standards, avoiding the use of materials derived from animals. The analytical methods applied have undergone systematic validation, and the final enzyme is subject to extensive quality control release testing to ensure it meets the requirements for use from research and development through to large-scale commercial production. Additionally, KACTUS has submitted MaxNuclease to the FDA Drug Master Files (DMF #036799).

Figure 13. Virus harvest solution was treated with 25U/mL and 50U/mL endonuclease at 37°C for 2 hours, respectively. Detection of plasmid DNA (pDNA) residue (left) and host cell DNA (HCD) (right) residue was analyzed. KACTUS MaxNuclease has higher degradation activity versus Competitor B demonstrated by lower pDNA and HCD residue for both 25U/mL and 50U/mL working concentrations.

MaxNuclease ELISA Kit

The quantification of residual MaxNuclease in gene therapy drugs is achievable with our associated ELISA kit, which provides a wide detection range of 46.88pg/mL to 3000pg/mL and sensitivity reaching up to 23.44pg/mL.

Figure 14. Example standard curve for MaxNuclease ELISA kit.

Browse Cell Therapy Products by Category

Class I and Class II MHC Monomers & Tetramers

Mammalian-Expressed Catalog & Custom Peptide-MHC Complexes

Class I and Class II Alleles

Product Features

Choice of Allele

Biotinylation & Fluorescent Labels

Verified Bioactivity

Shop by Allele

Class I Alleles – Human

HLA-A*01:01

Catalog No. Description Product Tag Exact Sequence
MHC-HM426 Human HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01),Ile21-Met119(B2M)and NTDNNLAVY peptide
MHC-HM427 Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01),Ile21-Met119(B2M)and EVDPIGHLY peptide
MHC-HM427T Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01),Ile21-Met119(B2M)and EVDPIGHLY peptide
MHC-HM426T Human HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01),Ile21-Met119(B2M)and NTDNNLAVY peptide
MHC-HM428 Human HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M)and YTDNWLAVY peptide.

HLA-A*02:03

Catalog No. Description Product Tag Exact Sequence
MHC-HM432TP PE-Labeled Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:03), Ile21-Met119(B2M) and FMNKFIYEI peptide
MHC-HM432 Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)and FMNKFIYEI peptide
MHC-HM432T Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)and FMNKFIYEI peptide
MHC-HM432B Biotinylated Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)and FMNKFIYEI peptide

HLA-A*03:01

Catalog No. Description Product Tag Exact Sequence
MHC-HM438 Human HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-C 03:04), Ile21-Met119(B2M)and GADGVGKSAL peptide
MHC-HM438B Biotinylated Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-C 03:04), Ile21-Met119(B2M)and GADGVGKSAL peptide
MHC-HM438T Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein C-His-Avi Gly25-Thr305 (HLA-C 03:04), Ile21-Met119 (B2M) and GADGVGKSAL peptide

HLA-A*24:02

Catalog No. Description Product Tag Exact Sequence
MHC-HM46RB Biotinylated Human Peptide Ready HLA-A*24:02&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-A*24:02) & Ile21-Met119(B2M)
MHC-HM46R Human Peptide Ready HLA-A*24:02&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-A*24:02) & Ile21-Met119(B2M)
MHC-HM433 Human HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and VYFFLPDHL peptide
MHC-HM433B Biotinylated Human HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and VYFFLPDHL peptide
MHC-HM434 Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and IMPKAGLLI peptide
MHC-HM434B Biotinylated Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and IMPKAGLLI peptide
MHC-HM434T Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and IMPKAGLLI peptide
MHC-HM430B Biotinylated Human HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and AYACNTSTL peptide
MHC-HM430 Human HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and AYACNTSTL peptide
MHC-HM430T Human HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and AYACNTSTL peptide

HLA-B*15:01

Catalog No. Description Product Tag Exact Sequence
MHC-HM448 Human HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein C-His-Avi Gly21-Thr301(HLA-B*15:01), Ile21-Met119(B2M) and NQKLIANQF peptide
MHC-HM448B Biotinlylated Human HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein C-His-Avi Gly21-Thr301(HLA-B*15:01), Ile21-Met119(B2M) and NQKLIANQF peptide

HLA-C*03:04

Catalog No. Description Product Tag Exact Sequence
MHC-HM438 Human HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-C 03:04), Ile21-Met119(B2M)and GADGVGKSAL peptide
MHC-HM438B Biotinylated Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-C 03:04), Ile21-Met119(B2M)and GADGVGKSAL peptide
MHC-HM438T Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein C-His-Avi Gly25-Thr305 (HLA-C 03:04), Ile21-Met119 (B2M) and GADGVGKSAL peptide

HLA-E*01:03

Catalog No. Description Product Tag Exact Sequence
MHC-HM406B Biotinylated Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer Protein C-His-Avi Gly25-Ile305(HLA-E*01:03), Ile21-Met119(B2M) and VMAPRTLVL peptide
MHC-HM406 Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer Protein C-His-Avi Gly25-Ile305(HLA-E*01:03), Ile21-Met119(B2M) and VMAPRTLVL peptide
MHC-HM42RB Biotinylated Human Peptide Ready HLA-E*01:03&B2M Monomer-Protein C-His-Avi Gly25-Ile305(HLA-E*01:03) & Ile21-Met119(B2M)
MHC-HM40C Human HLA-E*01:03&B2M&Peptide (VMAPKTLVL) Monomer Negative Control Protein C-His-Avi Gly25-Ile305(HLA-E*01:03), Ile21-Met119(B2M) and VMAPKTLVL peptide
MHC-HM42R Human Peptide Ready HLA-E*01:03&B2M Monomer-Protein C-His-Avi Gly25-Ile305(HLA-E*01:03) & Ile21-Met119(B2M)
MHC-HM406TB Biotinylated Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer Protein C-His-Avi Gly25-Ile305(HLA-E*01:03), Ile21-Met119(B2M)and VMAPRTLVL peptide
MHC-HM406T Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer Protein C-His-Avi Gly25-Ile305(HLA-E*01:03), Ile21-Met119(B2M) and VMAPRTLVL peptide

HLA-G

Catalog No. Description Product Tag Exact Sequence
HLG-HM41C Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-HM41CTB Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-HM41CT Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-HM41CB Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-HM41CTP PE-Labeled Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide
HLG-RM41C Rhesus macaque HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide
HLG-CM41C Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
MHC-HM45RB Biotinylated Human Peptide Ready HLA-G&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-G) & Ile21-Met119(B2M)
HLG-RM41CT Rhesus macaque HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-CM41CT Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
MHC-HM45R Human Peptide Ready HLA-G&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-G) & Ile21-Met119(B2M)
HLG-CM41CB Biotinylated Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G), Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-HE41F Human HLA-G Free Heavy Chain Protein C-His-Avi Gly25-Thr305(C66S)

Class I Alleles – Mouse

Qa-1b

Catalog No. Description Product Tag Exact Sequence
MHC-MM452 Mouse Qa-1b&B2M&Qdm (AMAPRTLLL) Monomer Protein C-His-Avi His23-Pro296(Qa-1b), Ile21-Met119(B2M) and AMAPRTLLL peptide

H-2Kb

Catalog No. Description Product Tag Exact Sequence
MHC-MM453 Mouse H-2K(b)&B2M&OVA (SIINFEKL) Monomer Protein C-His-Avi His24-Pro297(H-2K(b)), Ile21-Met119(B2M) and SIINFEKL peptide

Class II Alleles or Other Alleles

For other class I alleles, non-classical alleles, or class II alleles click here

Shop by Peptide Sequence

AFP (FMNKFIYEI)

Catalog No. Description Product Tag Exact Sequence
MHC-HM407B Biotinylated Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and FMNKFIYEI peptide
MHC-HM432TP PE-Labeled Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:03), Ile21-Met119(B2M) and FMNKFIYEI peptide
MHC-HM407TP PE-Labeled Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and FMNKFIYEI peptide
MHC-HM432 Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)and FMNKFIYEI peptide
MHC-HM432T Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)and FMNKFIYEI peptide
MHC-HM432B Biotinylated Human HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)and FMNKFIYEI peptide
MHC-HM407T Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and FMNKFIYEI peptide
MHC-HM407 Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and FMNKFIYEI peptide

AFP (PLFQVPEPV)

Catalog No. Description Product Tag Exact Sequence
MHC-HM408B Biotinylated Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and PLFQVPEPV peptide
MHC-HM408T Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and PLFQVPEPV peptide
MHC-HM408 Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and PLFQVPEPV peptide

CT83 (NTDNNLAVY)

Catalog No. Description Product Tag Exact Sequence
MHC-HM426 Human HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01),Ile21-Met119(B2M)and NTDNNLAVY peptide
MHC-HM426T Human HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01),Ile21-Met119(B2M)and NTDNNLAVY peptide

DSG3 (YTDNWLAVY)

Catalog No. Description Product Tag Exact Sequence
MHC-HM428 Human HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M)and YTDNWLAVY peptide

GP100 (YLEPGPVTA)

Catalog No. Description Product Tag Exact Sequence
MHC-HM402B Biotinylated Human HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YLEPGPVTA peptide
MHC-HM402 Human HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YLEPGPVTA peptide
MHC-HM402T Human HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YLEPGPVTA peptide
MHC-HM433 Human HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and VYFFLPDHL peptide
MHC-HM433B Biotinylated Human HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and VYFFLPDHL peptide

GP100 Intron 4 (VYFFLPDHL)

Catalog No. Description Product Tag Exact Sequence
MHC-HM433 Human HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and VYFFLPDHL peptide
MHC-HM433B Biotinylated Human HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and VYFFLPDHL peptide

HBV (FLLTRILTI)

Catalog No. Description Product Tag Exact Sequence
MHC-HM409 Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and FLLTRILTI peptide
MHC-HM409B Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and FLLTRILTI peptide
MHC-HM409T Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and FLLTRILTI peptide

HLA-E (VMAPRTLVL)

Catalog No. Description Product Tag Exact Sequence
MHC-HM406B Biotinylated Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer Protein C-His-Avi Gly25-Ile305(HLA-E*01:03), Ile21-Met119(B2M) and VMAPRTLVL peptide
MHC-HM406 Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer Protein C-His-Avi Gly25-Ile305(HLA-E*01:03), Ile21-Met119(B2M) and VMAPRTLVL peptide
MHC-HM406TB Biotinylated Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer Protein C-His-Avi Gly25-Ile305(HLA-E*01:03), Ile21-Met119(B2M)and VMAPRTLVL peptide
MHC-HM406T Human HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer Protein C-His-Avi Gly25-Ile305(HLA-E*01:03), Ile21-Met119(B2M) and VMAPRTLVL peptide

HLA-G (RIIPRHLQL)

Catalog No. Description Product Tag Exact Sequence
HLG-HM41C Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-HM41CTB Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-HM41CT Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-HM41CB Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-HM41CTP PE-Labeled Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide
HLG-RM41C Rhesus macaque HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide
HLG-CM41C Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-RM41CT Rhesus macaque HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-CM41CT Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-G),Ile21-Met119(B2M)and RIIPRHLQL peptide
HLG-CM41CB Biotinylated Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-G), Ile21-Met119(B2M)and RIIPRHLQL peptide

HLA-G Free Heavy Chain

Catalog No. Description Product Tag Exact Sequence
HLG-HE41F Human HLA-G Free Heavy Chain Protein C-His-Avi Gly25-Thr305(C66S)

HPV16 E6 (KLPQLCTEL)

Catalog No. Description Product Tag Exact Sequence
MHC-HM436 Human HLA-A*02:01&B2M&HPV 16 E6 (KLPQLCTEL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and KLPQLCTEL peptide
MHC-HM436T Human HLA-A*02:01&B2M&HPV 16 E6 (KLPQLCTEL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and KLPQLCTEL peptide

HPV16 E7 (YMLDLQPET)

Catalog No. Description Product Tag Exact Sequence
MHC-HM24MT Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide
MHC-HM424B Biotinylated Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide
MHC-HM424 Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide

HPV16 E7 (YMLDLQPET)

Catalog No. Description Product Tag Exact Sequence
MHC-HM24MT Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide
MHC-HM424B Biotinylated Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide
MHC-HM424 Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide

KRAS G12A (VVVGAAGVGK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM441 Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAAGVGK peptide
MHC-HM441T Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAAGVGK peptide
MHC-HM441B Biotinylated Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M)and VVVGAAGVGK peptide

KRAS G12C (VVVGACGVGK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM439B Biotinylated Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M)and VVVGACGVGK peptide
MHC-HM439 Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M)and VVVGACGVGK peptide
MHC-HM439T Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGACGVGK peptide

KRAS G12D (GADGVGKSAL)

Catalog No. Description Product Tag Exact Sequence
MHC-HM438 Human HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-C 03:04), Ile21-Met119(B2M)and GADGVGKSAL peptide
MHC-HM438B Biotinylated Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-C 03:04), Ile21-Met119(B2M)and GADGVGKSAL peptide
MHC-HM438T Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein C-His-Avi Gly25-Thr305 (HLA-C 03:04), Ile21-Met119 (B2M) and GADGVGKSAL peptide

KRAS G12D (VVGADGVGK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM420B Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGADGVGK peptide
MHC-HM420 Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGADGVGK peptide
MHC-HM454B Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119 (B2M) and VVVGADGVGK peptide
MHC-HM455B Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGADGVGK peptide
MHC-HM454 Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGADGVGK peptide
MHC-HM455 Human HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGADGVGK peptide
MHC-HM420TP PE-Labeled Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGADGVGK peptide
MHC-HM420T Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGADGVGK peptide

KRAS G12D (VVVGADGVGK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM420B Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGADGVGK peptide
MHC-HM420 Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGADGVGK peptide
MHC-HM454B Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119 (B2M) and VVVGADGVGK peptide
MHC-HM454 Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGADGVGK peptide
MHC-HM420TP PE-Labeled Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGADGVGK peptide
MHC-HM420T Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGADGVGK peptide

KRAS G12R (VVVGARGVGK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM440B Biotinylated Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M)and VVVGARGVGK peptide
MHC-HM440 Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M)and VVVGARGVGK peptide
MHC-HM440T Human HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGARGVGK peptide

KRAS G12S (VVVGASGVGK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM442 Human HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M)and VVVGASGVGK peptide
MHC-HM442B Biotinylated Human HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGASGVGK peptide
MHC-HM442T Human HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGASGVGK peptide

KRAS G12V (VVGAVGVGK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM422 Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGAVGVGK peptide
MHC-HM418B Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HM422B Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVGAVGVGK peptide
MHC-HM418TP PE-Labeled Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HM421 Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide
MHC-HM421B Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide
MHC-HE005 Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HE005B Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HE006B Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGAVGVGK peptide
MHC-HE006 Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGAVGVGK peptide
MHC-HM456 Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVGAVGVGK peptide
MHC-HM422T Human HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVGAVGVGK peptide
MHC-HM456B Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVGAVGVGK peptide
MHC-HM456TP PE-Labeled Human HLA-A*03:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVGAVGVGK peptide
MHC-HM421TP PE-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGAVGVGK peptide
MHC-HM421F FITC-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HM421T Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide
MHC-HM418T Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide
MHC-HM418 Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide

KRAS G12V (VVVGAVGVGK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM418B Biotinylated Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HM418TP PE-Labeled Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HM421 Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide
MHC-HM421B Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide
MHC-HE005TP PE-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HE005 Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HE005B Biotinylated Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HM421TP PE-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGAVGVGK peptide
MHC-HM421F FITC-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
MHC-HM421T Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide
MHC-HM418T Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide
MHC-HM418 Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide

KRAS WT (VVVGAGGVGK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM423B Biotinylated Human HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01) & Ile21-Met119(B2M)and VVVGAGGVGK peptide
MHC-HM423 Human HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01) & Ile21-Met119(B2M)and VVVGAGGVGK peptide
MHC-HM429B Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGAGGVGK peptide
MHC-HM429 Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGAGGVGK peptide
MHC-HE001B Biotinylated Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide
MHC-HE001 Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide
MHC-HM429TP PE-Labeled Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide
MHC-HM429F FITC-Labeled Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide
MHC-HM429T Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and VVVGAGGVGK peptide
MHC-HM423T Human HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01) & Ile21-Met119(B2M)and VVVGAGGVGK peptide

LMP2 (CLGGLLTMV)

Catalog No. Description Product Tag Exact Sequence
MHC-HM413T Chimeric HLA-A*02:01 (mα3) &B2M&LMP2 (CLGGLLTMV) Tetramer Protein C-His-Avi Gly25-Thr206(Human HLA-A*02:01 α1&α2) & Asp207-Glu299(Mouse H-2Ld α3), Ile21-Met119(B2M) and CLGGLLTMV peptide
MHC-HM413 Chimeric HLA-A*02:01 (mα3) &B2M&LMP2 (CLGGLLTMV) Monomer Protein C-His-Avi Gly25-Thr206(Human HLA-A*02:01 α1&α2) & Asp207-Glu299(Mouse H-2Ld α3), Ile21-Met119(B2M)and CLGGLLTMV peptide
MHC-HM411T Human HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and CLGGLLTMV peptide
MHC-HM411B Biotinylated Human HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and CLGGLLTMV peptide
MHC-HM411 Human HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and CLGGLLTMV peptide

LMP2 (SSCSSCPLTK)

Catalog No. Description Product Tag Exact Sequence
MHC-HM410B Biotinylated Human HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and SSCSSCPLTK peptide
MHC-HM410T Human HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and SSCSSCPLTK peptide
MHC-HM410 Human HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M)and SSCSSCPLTK peptide

MAGE-A1 (KVLEYVIKV)

Catalog No. Description Product Tag Exact Sequence
MHC-HM445B Biotinylated Human HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KVLEYVIKV peptide
MHC-HM445TP PE-Labeled Human HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KVLEYVIKV peptide
MHC-HM445 Human HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KVLEYVIKV peptide
MHC-HM445T Human HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KVLEYVIKV peptide

MAGE-A3 (EVDPIGHLY)

Catalog No. Description Product Tag Exact Sequence
MHC-HM427 Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01),Ile21-Met119(B2M)and EVDPIGHLY peptide
MHC-HM427T Human HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*01:01),Ile21-Met119(B2M)and EVDPIGHLY peptide

MAGE-A3 (IMPKAGLLI)

Catalog No. Description Product Tag Exact Sequence
MHC-HM434 Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and IMPKAGLLI peptide
MHC-HM434B Biotinylated Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and IMPKAGLLI peptide
MHC-HM434T Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and IMPKAGLLI peptide

MAGE-A4 (GVYDGREHTV)

Catalog No. Description Product Tag Exact Sequence
MHC-HM401B Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and GVYDGREHTV peptide
MHC-HM401 Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and GVYDGREHTV peptide
MHC-HM401TP PE-Labeled Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and GVYDGREHTV peptide
MHC-HM401T Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and GVYDGREHTV peptide

MAGE-A4 (KVLEHVVRV)

Catalog No. Description Product Tag Exact Sequence
MHC-HM106 Chimeric HLA-A*02:01 (mα3) &mB2M&MAGE-A4 (KVLEHVVRV) Monomer Protein C-His Gly25-Thr206(Human HLA-A*02:01 α1&α2) & Asp207-Glu299(Mouse H-2Ld α3), Ile21-Met119(mB2M) and KVLEHVVRV peptide
MHC-HM437B Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KVLEHVVRV peptide
MHC-HM437 Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KVLEHVVRV peptide

MAGE-A8 (KVLEHVVRV)

Catalog No. Description Product Tag Exact Sequence
MHC-HM106 Chimeric HLA-A*02:01 (mα3) &mB2M&MAGE-A4 (KVLEHVVRV) Monomer Protein C-His Gly25-Thr206(Human HLA-A*02:01 α1&α2) & Asp207-Glu299(Mouse H-2Ld α3), Ile21-Met119(mB2M) and KVLEHVVRV peptide
MHC-HM437B Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KVLEHVVRV peptide
MHC-HM437 Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KVLEHVVRV peptide

MART-1 (ELAGIGILTV)

Catalog No. Description Product Tag Exact Sequence
MHC-HM435 HLA-A*02:01&B2M&MART-1 (ELAGIGILTV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M)and ELAGIGILTV peptide
MHC-HM435T Human HLA-A*02:01&B2M&MART-1 (ELAGIGILTV) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M)and ELAGIGILTV peptide

NY-ESO-1 (SLLMWITQC)

Catalog No. Description Product Tag Exact Sequence
MHC-HM151 Chimeric HLA-A*02:01 (mα3) &mB2M&NY-ESO-1 (SLLMWITQC) Monomer Protein C-His Gly25-Thr206(Human HLA-A*02:01 α1&α2) & Asp207-Glu299(Mouse H-2Ld α3), Ile21-Met119(mB2M) and SLLMWITQC peptide
MHC-HE446 Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQC peptide
MHC-HE446T Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQC peptide
MHC-HM405TP PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQC peptide
MHC-HM405T Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQC peptide
MHC-HM405B Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M)and SLLMWITQC peptide
MHC-HM405 Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and SLLMWITQC peptide

NY-ESO-1 (SLLMWITQV)

Catalog No. Description Product Tag Exact Sequence
MHC-HM40N Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and SLLMWITQV peptide
MHC-HM40NT Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and SLLMWITQV peptide
MHC-HM40NB Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and SLLMWITQV peptide

p53-R175H (HMTEVVRHC)

Catalog No. Description Product Tag Exact Sequence
MHC-HM415B Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRHC peptide
MHC-HM415TP PE-Labeled Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRHC peptide
MHC-HM415T Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRHC peptide
MHC-HM415 Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRHC peptide

p53 WT (HMTEVVRRC)

Catalog No. Description Product Tag Exact Sequence
MHC-HM416B Biotinylated Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRRC peptide
MHC-HM416TP PE-Labeled Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRRC peptide
MHC-HM416T Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRRC peptide
MHC-HM416 Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and HMTEVVRRC peptide

PRAME (ALYVDSLFFL)

Catalog No. Description Product Tag Exact Sequence
MHC-HM447B Biotinylated Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and ALYVDSLFFL peptide
MHC-HM447T Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and ALYVDSLFFL peptide
MHC-HM447 Human HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and ALYVDSLFFL peptide

PRAME (SLLQHLIGL)

Catalog No. Description Product Tag Exact Sequence
MHC-HM443B Biotinylated Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M)and SLLQHLIGL peptide
MHC-HM443 Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M)and SLLQHLIGL peptide
MHC-HM443T Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M)and SLLQHLIGL peptide
MHC-HM443TP PE-Labeled Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M)and SLLQHLIGL peptide

SARS-CoV-2 Epitope (NQKLIANQF)

Catalog No. Description Product Tag Exact Sequence
MHC-HM448 Human HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein C-His-Avi Gly21-Thr301(HLA-B*15:01), Ile21-Met119(B2M) and NQKLIANQF peptide
MHC-HM448B Biotinlylated Human HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein C-His-Avi Gly21-Thr301(HLA-B*15:01), Ile21-Met119(B2M) and NQKLIANQF peptide

Survivin (LMLGEFLKL)

Catalog No. Description Product Tag Exact Sequence
MHC-HM412T Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and LMLGEFLKL peptide
MHC-HM412B Biotinylated Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and LMLGEFLKL peptide
MHC-HM412 Human HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and LMLGEFLKL peptide

Survivin 2B (AYACNTSTL)

Catalog No. Description Product Tag Exact Sequence
MHC-HM430B Biotinylated Human HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and AYACNTSTL peptide
MHC-HM430 Human HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and AYACNTSTL peptide
MHC-HM430T Human HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M)and AYACNTSTL peptide

WT-1 (RMFPNAPYL)

Catalog No. Description Product Tag Exact Sequence
MHC-HM431B Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and RMFPNAPYL peptide
MHC-HM431T Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and RMFPNAPYL peptide
MHC-HM431 Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer Protein C-His-Avi Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and RMFPNAPYL peptide
MHC-HM414T Chimeric HLA-A*02:01 (mα3) &B2M&WT-1 (RMFPNAPYL) Tetramer Protein C-His-Avi Gly25-Thr206(Human HLA-A*02:01 α1&α2) & Asp207-Glu299(Mouse H-2Ld α3), Ile21-Met119(B2M)and RMFPNAPYL peptide
MHC-HM414 Chimeric HLA-A*02:01 (mα3) &B2M&WT-1 (RMFPNAPYL) Monomer Protein C-His-Avi Gly25-Thr206(Human HLA-A*02:01 α1&α2) & Asp207-Glu299(Mouse H-2Ld α3), Ile21-Met119(B2M) and RMFPNAPYL peptide

Custom Peptide

For MHCs with custom peptide sequences,click here.

Alternatively, try a Peptide-Ready MHC to load your peptide in-house onto an MHC tetramer or monomer.

Product Validation Data

Human NY-ESO-1 (HLA-A*02:01) Tetramer

Anti-NY-ESO-1 (HLA-A*02:01) Antibody, hFc Tag captured on CM5 Chip via Protein A can bind Human NY-ESO-1 (HLA-A*02:01) Tetramer, His Tag with an affinity constant of 0.09 nM as determined in SPR assay (Biacore T200).

Human KRAS G12V (HLA-A*03:01)

Human KRAS G12V (HLA-A*03:01) , His Tag captured on CM5 Chip via anti-his antibody can bind Anti-KRAS G12V (HLA-A*03:01) Antibody with an affinity constant of 0.11 μM as determined in SPR assay (Biacore T200).

Biotinylated Human P53 R175H (HLA-A*02:01)

Immobilized Anti-P53 R175H (HLA-A*02:01) Antibody, hFc Tag at 5μg/mL (100μL/well) on the plate. Dose response curve for Biotinylated Human P53 R175H (HLA-A*02:01) , His Tag with the EC50 of 1.6μg/mL determined by ELISA.

Human NY-ESO-1 (HLA-A*02:01) Tetramer

As verified by ELISA, the activity of NY-ESO-1 (HLA-A*02:01) tetramer expressed in mammalian cells and E. coli is comparable, providing you with more choices for research.

Peptide-Ready MHC: Load your own peptide

Load your own MHC monomer or tetramer in-house with our peptide-free MHCs.

→ Quick & simple peptide loading procedure

→ Monomer / Tetramer

→ Fluorescent Labeling

→ Class I and Class II Alleles

→ Biotinylation

MHC Product Types

Monomers

Our MHC peptide monomers are mammalian-expressed to ensure the natural configuration and have a His-Avi tag at the C-terminus. The Avi tag is a 15-amino acid sequence, which has a high affinity for biotin and can be specifically biotinylated by BirA.

Tetramers

MHC tetramers are complexes of four peptide-MHC biotinylated monomers bound to streptavidin molecules. The enhanced avidity of MHC tetramers and TCR interactions can have a significant impact for detecting antigen-specific T cells. They allow for direct detection, phenotyping, and enumeration of antigen-specific T cells within a polyclonal T cell population. KACTUS offers class I and class II tetramers.

Fluorescent Tetramer

Fluorescent MHC tetramers can be used to identify T cells that recognize a particular peptide-MHC complex. By labeling T cells with MHC tetramers, the frequency and distribution of antigen-specific T cells can be determined and sorted by FACS in a cell population. MHC tetramers can also be used to monitor immune responses to vaccines, infections and diseases by measuring the frequency of antigen-specific T cells over time to track the efficacy of a treatment.

MHC-I Virus-Like Particles

In combination with our Virus-Like Particles (VLP) technology platform, we have introduced multivalent fluorescent MHC I. These MHC I-VLP complexes are about 750 Å in diameter, compared to the MHC I monomer size of 70 Å. Each VLP contains approximately 250 copies of MHC I, resulting in boosted fluorescence quantum yield for enhanced detection of TCR binding. We currently offer FITC- and APC-equivalent options for MHC I-VLP fluorescence labeling.

Peptide-Ready MHC

Neoantigens offer a distinct advantage in their unique tumor-specific and normal tissue-absent feature, presenting ideal targets for effective and personalized tumor-specific immunotherapy. We have developed Peptide-Ready MHCs (prMHC), which are composed only of the α heavy chain and β2-microglobulin (β2m) light chain for loading your own neoantigen.

Chimeric MHC

Chimeric MHCs have the human α3 immunoglobulin-like domain replaced with the mouse α3 domain. This modification enhances antigen specificity for antibody discovery. These mammalian-expressed Chimeric MHCs retain their normal conformation to increase the likelihood of generating peptide-specific antibodies while decreasing the frequency of non-specific antibodies and making screening less labor-intensive.

Custom MHC Complexes

Choice of mammalian or E. coli expression systems

Monomers, Tetramers, Biotinylation, Fluorescent Labels

Multi-faceted biological activity verification (ELISA, SPR, FACS, etc.)

Choice of Class I or Class II Alleles

Choice of PE, APC, or other fluorescent label

Various species: Human, mouse, monkey, etc.

Soluble TCR Expression & SPR Analysis

→ Production of various formats of soluble TCRs, including scFv-TCR, TCR-His, etc.

→ TCR engineering to optimize soluble TCR expression based on TCR modeling

→ SPR analysis of soluble TCR & Peptide-Ready MHC/Peptide-MHC interactions

HLA-G and LILRs

→ HLA-G Monomers and Tetramers

→ LILRAs and LILRBs

→ APOE Proteins

→ Custom HLA-G & LILR Proteins

Major Histocompatibility Complex

The MHC (Major Histocompatibility Complex) is a major histocompatibility complex, which is a highly polymorphic family of cell surface proteins, also known as HLA in humans. MHC can bind to peptide fragments of intracellular antigens to form MHC-peptide complexes, which are then transported to the cell surface and recognized by the corresponding T cell receptor (TCR) to initiate an immune response.

In humans, the main types of MHC involved in antigen presentation are MHC I and MHC II. MHC I, after binding antigen peptides, is recognized by CD8+ T cells, while MHC II, after binding peptides, is recognized by CD4+ T cells. MHC-peptide complexes represent a category of intracellular antigen targets. Their unique binding pattern with TCR plays a crucial role not only in adaptive immune processes but also holds significance for TCR-related therapies such as TCR-T development.

Mechanism of MHC involvement in antigen presentation (Anthony W. Purcell, et al., 2019)

MHC Class I (MHC-I)

MHC-I molecules play a crucial role in the immune system by presenting peptide antigens to cytotoxic T cells. These heterotrimers consist of a transmembrane MHC heavy chain, a light chain known as β2-microglobulin (β2m), and an 8-10 peptide antigen. The heavy chain contains two peptide binding domains (α1 and α2), an immunoglobulin-like domain (α3), and a transmembrane region. The folding of the α1 and α2 domains forms a groove where peptide antigens bind to the MHC-I molecule. β2m stabilizes the peptide binding groove and MHC I presentation.

A single nucleated cell expresses 5×10⁵ copies of each MHC I molecule, presenting a variety of peptides simultaneously on the cell surface to CTLs. Accumulating genomic mutations in cancers result in the production of tumor-specific antigens or neoantigens, which can be presented by MHC I molecules of tumor cells to CTLs.

MHC Class 1 complex (MHC-I) containing an α-chain spanning the cell membrane and an extracellular β2m (β2-microglobulin) connected to this chain.

References

1. Kurosawa et al., Development of a T‐cell receptor mimic antibody targeting a novel Wilms tumor 1‐derived peptide and analysis of its specificity. Cancer Sci. 2020 Oct; 111(10): 3516–3526.

2. Doubrovina et al., Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. Blood. 2012 Aug 23;120(8):1633-46

Quick and simple in-house peptide loading for custom MHC monomers or tetramers

What are prMHCs?

KACTUS peptide-ready MHCs (prMHC) are MHC monomers and tetramers absent of antigenic peptides. The prMHCs are stabilized and ready for loading the neoantigen peptide of your choosing. They are ideal for generating custom MHC peptide tetramers and high throughput peptide screening. The prMHCs are expressed from HEK293 cells and have >95% purity.

Do you offer a peptide-loading protocol?

KACTUS offers a quick and simple protocol for loading peptides in-house. Contact us to receive the protocol.

Class I Peptide-Ready MHC (prMHC).

What can I do with a prMHC?

Assess MHC/TCR Binding Affinity

Enabling rapid and high-quality creation of custom Class I and II MHC tetramers, our Peptide-Ready MHCs (prMHC) provide a streamlined and user-friendly approach to developing new custom MHC monomers and tetramers in just a few minutes directly in your lab. Simply by mixing your peptide of interest with one of our prMHCs and incubating at room temperature, you generate a Peptide-MHC complex, which can be utilized for the creation of custom MHC tetramers and monomers or employed in high-throughput screening of peptides. This innovative system holds applications across various realms including epitope discovery, neoantigen vaccine research, and verification of T cell staining, among others.

Generate a custom MHC peptide monomer or tetramer

In neoantigen identification, assessing the immune functionality of the antigenic peptide is critical, which includes evaluating its binding affinity to MHC and its reactivity with TCR. To facilitate this, KACTUS has introduced a range of functional Peptide-Ready MHCs products. These can serve as a ready-to-use loading system to assist in loading antigen peptides and subsequently form a new, complete MHC peptide complex, thereby significantly aiding your neoantigen research studies by ensuring efficiency and reliability.

High Throughput Peptide Screening

prMHCs are instrumental in the functional screening of peptides for MHC class I binding, a critical component in vaccine design and immune monitoring. They provide the distinct ability to discriminate between MHC binding and non-binding peptides, which is particularly pivotal when screening immunogenic peptides derived from infectious agents or cancer neoantigens. Subsequently, the generated Peptide-MHC complexes can be used for immune monitoring.

Shop Alleles

Browse available alleles in our stabilized peptide-free form.

HLA-A*02:01

Catalog No. Description Product Tag Exact Sequence
MHC-HM43RB Biotinylated Human Peptide Ready HLA-A*02:01&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-A*02:01) & Ile21-Met119(B2M)
MHC-HM43R Human Peptide Ready HLA-A*02:01&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-A*02:01) & Ile21-Met119(B2M)
MHC-HM43RTC APC-equivalent Human Peptide Ready HLA-A*02:01&B2M Tetramer Protein C-His Gly25-Thr305(HLA-A*02:01) & Ile21-Met119(B2M)

HLA-A*03:01

Catalog No. Description Product Tag Exact Sequence
MHC-HM44RTP PE-Labeled Human Peptide Ready HLA-A*03:01&B2M Tetramer Protein C-His-Avi Gly25-Thr305(HLA-A*03:01) & Ile21-Met119(B2M)
MHC-HM44RB Biotinylated Human Peptide Ready HLA-A*03:01&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-A*03:01) & Ile21-Met119(B2M)

HLA-G

Catalog No. Description Product Tag Exact Sequence
MHC-HM45RB Biotinylated Human Peptide Ready HLA-G&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-G) & Ile21-Met119(B2M)
MHC-HM45R Human Peptide Ready HLA-G&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-G) & Ile21-Met119(B2M)

HLA-A*11:01

Catalog No. Description Product Tag Exact Sequence
MHC-HM41RB Biotinylated Human Peptide Ready HLA-A*11:01&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-A*11:01) & Ile21-Met119(B2M)
MHC-HM41RTP PE-Labeled Human Peptide Ready HLA-A*11:01&B2M Tetramer-Protein C-His-Avi Gly25-Thr305(HLA-A*11:01) & Ile21-Met119(B2M)
MHC-HM41R Human Peptide Ready HLA-A*11:01&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-A*11:01) & Ile21-Met119(B2M)

HLA-A*24:02

Catalog No. Description Product Tag Exact Sequence
MHC-HM46RTF FITC-equivalent Human Peptide Ready HLA-A*24:02&B2M Tetramer Protein C-His Gly25-Thr305(HLA-A*24:02) & Ile21-Met119(B2M)
MHC-HM46RTC APC-equivalent Human Peptide Ready HLA-A*24:02&B2M Tetramer Protein C-His Gly25-Thr305(HLA-A*24:02) & Ile21-Met119(B2M)
MHC-HM46RB Biotinylated Human Peptide Ready HLA-A*24:02&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-A*24:02) & Ile21-Met119(B2M)
MHC-HM46R Human Peptide Ready HLA-A*24:02&B2M Monomer-Protein C-His-Avi Gly25-Thr305(HLA-A*24:02) & Ile21-Met119(B2M)

HLA-E*01:03

Catalog No. Description Product Tag Exact Sequence
MHC-HM42RB Biotinylated Human Peptide Ready HLA-E*01:03&B2M Monomer-Protein C-His-Avi Gly25-Ile305(HLA-E*01:03) & Ile21-Met119(B2M)
MHC-HM42R Human Peptide Ready HLA-E*01:03&B2M Monomer-Protein C-His-Avi Gly25-Ile305(HLA-E*01:03) & Ile21-Met119(B2M)

Other Alleles

KACTUS supports expression of other MHC alleles including class II alleles and non-human species.

Browse All Available Products

Browse our selection of in-stock Peptide-Ready MHC Complexes.

Order Now Type Allele Species Tag Express system Purity
MHC-HM43R Monomer HLA-A*02:01&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM43RB Biotinylated Monomer HLA-A*02:01&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM43RTC APC-Equivalent Tetramer HLA-A*02:01&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM44R Monomer HLA-A*03:01&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM44RB Biotinylated Monomer HLA-A*03:01&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM41R Monomer HLA-A*11:01&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM41RB Biotinylated Monomer HLA-A*11:01&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM42R Monomer HLA-E*01:03&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM42RB Biotinylated Monomer HLA-E*01:03&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM45R Monomer HLA-G&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM45RB Biotinylated Monomer HLA-G&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM46R Monomer HLA-A*24:02&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC
MHC-HM46RB Biotinylated Monomer HLA-A*24:02&B2M Human C-His-Avi HEK293 > 95% via Tris-Bis Page & HPLC

Performance Validation of prMHCs

Figure 1. Demonstrated via ELISA assay, biotinylated Human Peptide Ready HLA-A*11:01&B2M Monomer loaded peptide (VVVGADGVGK) has a high affinity with HLA-A*11:01&B2M&KRAS G12D TCR. The EC50 is 110 ng/mL.

Figure 2. Demonstrated via SPR assay, biotinylated Human Peptide Ready HLA-A*11:01&B2M Monomer loaded with peptide (VVVGADGVGK) has a high affinity with HLA-A*11:01&B2M&KRAS G12D TCR. The affinity constant is 8.5 nM.

Figure 3. Demonstrated via SPR assay, Human Peptide Ready HLA-A*02:01&B2M& Monomer loaded with peptide (FMNKFIYEI) has a good affinity with HLA-A*02:01&B2M&AFP TCR. The affinity constant is 0.32 µM.

Figure 4. Demonstrated via FACS assay, fluorescent-labeled Human Peptide-Ready HLA-A*02:01&B2M Tetramer loaded with peptide (SLLMWITQC) can bind with HLA-A*02:01&B2M&NY-ESO-1 TCR cells.

Stability Testing of KACTUS prMHCs

Freeze Thaw Stability

KRAS G12D peptide was added to biotinylated human HLA-A*11:01 and freeze thawed up to five times. Activity was analyzed via ELISA. Immobilized TCR was added to the plate at 2μg/mL (100μL/well). Results are a dose response curve for Biotinylated
Human KRASG12D (HLA-A*11:01), His Tag with EC50s of 0.22/0.16/0.18/0.15/0.15/19 μg/mL.

Biotinylated human HLA-A*11:01 was freeze-thawed up to five times after which KRAS G12D peptide was added. Activity was analyzed via ELISA. Immobilized TCR was added to the plate at 2μg/mL (100μL/well). Results are a dose response curve for Biotinylated Human KRASG12D (HLA-A*11:01), His Tag with EC50s of 0.21/0.13/0.18/0.16/0.16 μg/mL.

Stability Testing at 4C

KRAS G12D peptide was added to biotinylated human HLA-A*11:01 and incubated at 4℃ for 0, 7, 14, and 21 days. Activity was analyzed via ELISA. Immobilized TCR was added to the plate at 2µg/mL (100µL/well). Results show a dose-response curve for Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) monomer, His Tag with EC50s of 0.19/0.11/0.13/0.14/0.16 µg/mL.

Biotinylated human HLA-A*11:01 was incubated at 4°C for 0, 7, 14, and 21 days, after which KRAS G12D peptide was added. Activity was analyzed via ELISA. Immobilized TCR was added to the plate at 2µg/mL (100µL/well) on the plate. Results show a dose-response curve for Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) monomer, His tag with EC50s of 0.16/0.11/0.26/0.32/0.36 µg/mL.

Stability Testing at 37C

KRAS G12D peptide was added to biotinylated human HLA-A*11:01 and incubated at 37℃ for 0, 1, 3, and 5 days. Activity was analyzed via ELISA. Immobilized TCR was added to the plate at 2µg/mL (100µL/well). Results show a dose response curve for biotinylated human KRAS G12D (HLA-A*11:01), His tag with EC50s of 0.19/0.22/0.16/0.22/0.29/10.56 µg/mL.

Biotinylated human HLA-A*11:01 was incubated at 37℃ for 0, 1, 3, and 5 days, after which KRAS G12D peptide was added. Activity was analyzed via ELISA. Immobilized TCR was added to the plate at 2µg/mL (100µL/well). Results show a dose-response curve for Biotinylated Human KRAS G12D (HLA-A*11:01), His tag with EC50s of 0.19/0.22/0.52/0.46/0.43 µg/mL.

Neoantigen Peptides and Their Role in MHC/TCR Interactions

Neoantigens are highly specific targets and ideal targets for immunotherapy. Degraded neoantigen peptides can bind with major histocompatibility complex (MHC) molecules, forming complexes that are subsequently transported to the cell surface. These complexes are recognized by T-cell receptor (TCR), triggering an immune response. MHC polypeptide complexes constitute a category of neoantigen targets, and their distinctive interaction with TCR holds immense importance in the advancement of neoantigen-based immunotherapies, including TCR-T cell therapy, antibody drugs, and tumor vaccines.

Identification of the affinity of peptide loaded MHC with TCR [1].

prMHC FAQs

Our Products

What prMHC products does KACTUS provide?

KACTUS provides catalog and customized prMHC monomers, biotinylated monomers, and fluorescent tetramers.

What quality control is done for KACTUS prMHCs?

We analyze prMHC products for molecular weight (Tris-Bis PAGE), purity (Tris-Bis PAGE & SEC-HPLC), endotoxin, and concentration. Our prMHC products have > 95% purity and < 1 EU/µg.

Does KACTUS provide custom prMHC class I and prMHC class II molecules?

Yes, KACTUS provides custom prMHC-I and prMHC-II for all available MHC alleles. Contact us at info@stratech.co.uk to request a custom MHC.

What is the shelf life of a prMHC?

prMHCs can be stored for at least 12 months at -80°C.

About Peptide-Ready MHCs

What are prMHCs?

Peptide-ready MHCs (prMHC) is an MHC that doesn’t contain any pre-loaded peptide and can be loaded with custom peptides for TCR binding and cell staining.

What is a prMHC monomer?

A prMHC monomer consists of an α-chain and β-2 microglobulin. It is a single subunit of prMHC tetramer.

What is a biotinylated prMHC monomer?

It is a prMHC monomer with biotin at the C-terminal Avi tag.

What is a fluorescent prMHC tetramer?

A fluorescent prMHC tetramer is a complex of four prMHC monomers with fluorophores conjugated to each monomer subunit of the prMHC complex.

Expression of prMHCs

Are KACTUS prMHCs a proprietary design?

Yes, KACTUS prMHCs are a propriety design based on our SAMS™ Protein Engineering Platform.

Are prMHCs made using single-chain expression?

Yes, prMHC are a single-chain design of α-chain and β-2 microglobulin developed by our protein engineering team.

How are prMHCs purified?

prMHCs are affinity-purified via His tag at the C-terminus with additional size exclusion chromatography steps.

Are the prMHCs expressed in mammalian cells?

Yes, prMHCs are purified from HEK293 cells.

Are the prMHC tetramers made by in vitro assembly using streptavidin?

No, prMHC tetramerize in vivo during expression in HEK293, a KACTUS propriety design.

Fluorescent Labeling

Which fluorophores are available for prMHC tetramers?

We currently offer APC-equivalent, FITC-equivalent and PE conjugation for prMHC tetramers.

What are the properties of APC-equivalent fluorophores?

APC-equivalent is a 90 kDa protein, with excitation peak at 609 nm and emission peak at 643 nm.

Is APC-equivalent labeling done in vitro for prMHC tetramers?

No, APC-equivalent is an in vivo label, part of KACTUS proprietary single chain design for fluorescent prMHC tetramer.

Protocols & Applications

Can you provide a tetramer staining protocol using prMHC?

Yes, contact orders@stratech.co.uk for a protocol.

Can you provide a prMHC peptide loading protocol?

Yes, contact orders@stratech.co.uk for a protocol.

Can KACTUS prMHCs be used for peptide screening?

Yes, KACTUS prMHCs can be used for peptide screening.

References

[1] Moritz A, Anjanappa R, Wagner C, Bunk S, Hofmann M, Pszolla G, Saikia A, Garcia-Alai M, Meijers R, Rammensee HG, Springer S, Maurer D. High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules. Sci Immunol. 2019 Jul 19;4(37):eaav0860.

Unlock the Potential of First-in-Class Drug Discovery with Recombinant HLA-G and LILR Products

Novel Combination of Targets in Immune Response and Drug Discovery

LILRs

Leukocyte Immunoglobulin-Like Receptors (LILRs) are a family of receptors primarily expressed on immune cells, playing critical roles in modulating immune responses. They are type I transmembrane glycoproteins characterized by the presence of extracellular immunoglobulin-like domains. LILRs can be activating (LILRAs) or inhibitory (LILRBs), with the inhibitory receptors possessing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic tails. These receptors recognize a variety of ligands, including major histocompatibility complex (MHC) class I molecules, and their interaction with these ligands can influence the function of various immune cells, including dendritic cells, macrophages, and T and B lymphocytes.

Through these interactions, LILRs contribute to the regulation of both innate and adaptive immune responses, playing roles in immune tolerance, inflammation, and the defense against pathogens. Their dysregulation has also been implicated in various diseases, including autoimmune conditions, cancer, and infectious diseases. This highlighting their importance in immune

Figure 1. LILRB binding ligands.

HLA-G

MHC-I proteins present antigenic peptides and are recognized by associated receptors. This enables the immune system to detect self-antigens and eliminate targets lacking self-antigens or expressing foreign antigens. Human leukocyte antigen G (HLA-G) is a non-classical human MHC class Ib molecule. It is an important immune tolerance molecule in the body, contributing to immune escape or immune cell anergy. In recent years, it has been regarded as a new type of immune checkpoint.

HLA-G, like other immune checkpoints, mediates its function by binding to receptors on immune cells. The known receptors of HLA-G are leukocyte Ig-like receptor subfamily B member 1 (LILRB1) and member 2 (LILRB2) which belong to the Leukocyte Ig-like receptor (LILR) family. LILRs are one kind of these receptors that either activates (LILRA members) or suppresses (LILRB members) immune cell functions. When HLA-G binds to LILRBs, tumor cells can escape the surveillance of the immune system. As LILRBs have a similar immunoreceptor tyrosine-based inhibitory motif (ITIM) like immune checkpoint proteins such as CTLA4 and PD-1, they’ve become hot targets for drug development, especially for discovery of first-in-class drugs.

Multiple clinical/preclinical studies show the potential broad anti-tumor effects of LILR family proteins, such as BND-22 (Biond), IO-202 (Immune Onc), JTX-8064 (Jounce Therapeutics) and NC410 (NextCure). In addition, since the expression profile of HLA-G is significantly different from that of PD-L1, HLA-G antibodies might be able to enhance tumor sensitivity to anti-PD-L1 therapy. This would be a novel breakthrough for patients with tumors that do not respond to anti-PD-L1 therapy.

Performance Validation

Figure 2. Human LILRB2, hFc Tag captured on CM5 Chip via Protein A can bind Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer with an affinity constant of 4.62 nM as determined in SPR assay (Biacore T200).

Figure 3. Rhesus macaque LILRB1, hFc Tag captured on CM5 Chip via Protein A can bind Rhesus macaque HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His Tag with an affinity constant of 1.74 nM as determined in SPR assay (Biacore T200).

Figure 4. Cynomolgus LILRB2, His Tag immobilized on CM5 Chip can bind Cynomolgus HLA-G Complex Tetramer, His Tag with an affinity constant of 852 nM as determined in SPR assay (Biacore T200).

Figure 5. Serial dilutions of Anti-LILRB2 Antibody were added into Human LILRB2, His Tag : Biotinylated HLA-G Complex Tetramer, His Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 75.3ng/ml.

Product Lists

HLA-G Products

KACTUS has developed a full portfolio of mammalian-expressed HLA-G monomers and tetramers including biotinylated versions. Our HLA-G monomers and tetramers are mammalian-expressed from HEK293 cells and have >95% purity with low endotoxin (<1EU/ug). HLA-G monomers and tetramers can be used for antibody discovery, TCR binding, and flow cytometry. We also offer custom HLA-G tetramers. Contact us today to learn more.

Catalog # Species Tag Target Express System
HLG-HE41F Human C-His-Avi HLA-G Free Heavy Chain E.coli
HLG-HM41CB Human C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Monomer HEK293
HLG-CM41CB Cynomolgus C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Monomer HEK293
HLG-CM41C Cynomolgus C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Monomer HEK293
HLG-HM41C Human C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Monomer HEK293
HLG-RM41C Rhesus macaque C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Monomer HEK293
HLG-HM41CTB Human C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer HEK293
HLG-CM41CT Cynomolgus C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer HEK293
HLG-HM41CT Human C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer HEK293
HLG-HM41CTP Human C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer HEK293
HLG-RM41CT Rhesus macaque C-His-Avi HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer HEK293
MHC-HM45RB Human C-His-Avi Peptide Ready HLA-G&B2M Monomer HEK293
MHC-HM45R Human C-His-Avi Peptide Ready HLA-G&B2M Monomer HEK293

LILRA, LILRB, and APOE Products

Using our SAMS protein engineering platform, we have developed a large portfolio of LILRA and LILRB catalog products. These products are expressed from HEK293 cells and are available in multiple species, including human, mouse, cynomolgus, and rhesus macaque as well as biotinylated versions. Contact us today to request a custom LILR.

Catalog # Target Species Biotinylated Tag Exact Sequence Express System
APO-MM102 APOE/Apolipoprotein E Mouse No C-His Glu19-Gln311 HEK293
APO-MM202 APOE/Apolipoprotein E Mouse No C-hFc Glu19-Gln311 HEK293
APO-HM101B APOE3/Apolipoprotein E Human Yes N-His Lys19-His317 HEK293
APO-HM101 APOE3/Apolipoprotein E Human No N-His Lys19-His317 HEK293
APO-HM203 APOE3/Apolipoprotein E Human No N-hFc Lys19-His317 HEK293
APO-HM202 APOE4/Apolipoprotein E Human No N-hFc Lys19-His317 HEK293
APO-HM102 APOE4/Apolipoprotein E Human No N-His Lys19-His317 HEK293
LIL-HM4A1 LILRA1/CD85i/LIR-6 Human No C-His-Avi Pro17-Asn461 HEK293
LIL-HM4A1B LILRA1/CD85i/LIR-6 Human Yes C-His-Avi Pro17-Asn461 HEK293
LIL-HM4A2 LILRA2/CD85h/ILT1 Human No C-His-Avi Gly24-Asn449 HEK293
LIL-HM4A2B LILRA2/CD85h/ILT1 Human Yes C-His-Avi Gly24-Asn449 HEK293
LIL-HM4A3B LILRA3/CD85e Human Yes C-His-Avi Gly24-Glu439 HEK293
LIL-HM4A3 LILRA3/CD85e Human No C-His-Avi Gly24-Glu439 HEK293
LIL-CM1A4 LILRA4/CD85g Cynomolgus No C-His Glu24-Asn446 HEK293
LIL-HM4A4 LILRA4/CD85g Human No C-His-Avi Glu24-Asn446 HEK293
LIL-HM4A4B LILRA4/CD85g Human Yes C-His-Avi Glu24-Asn446 HEK293
LIL-HM4A5B LILRA5/CD85f/ILT11 Human Yes C-His-Avi Gly42-Arg268 HEK293
LIL-HM4A5 LILRA5/CD85f/ILT11 Human No C-His-Avi Gly42-Arg268 HEK293
LIL-HM4A6 LILRA6/CD85b/ILT8 Human No C-His-Avi Gly24-Asn447 HEK293
LIL-HM4A6B LILRA6/CD85b/ILT8 Human Yes C-His-Avi Gly24-Asn447 HEK293
LIL-CM1A6 LILRA6/CD85b/ILT8 Cynomolgus No C-His Gly41-His474 HEK293
LIL-CM1B3 LILRB1/CD85j/ILT2 Rhesus macaque No C-His Met1-His474 HEK293
LIL-CM1B1 LILRB1/CD85j/ILT2 Rhesus macaque No C-His Ser17-His456 HEK293
LIL-CM2B1 LILRB1/CD85j/ILT2 Rhesus macaque No C-hFc Ser17-His456 HEK293
LIL-CM2B3 LILRB1/CD85j/ILT2 Rhesus macaque No C-hFc Met1-His474 HEK293
LIL-HM13D LILRB1/CD85j/ILT2 Human No C-His Leu116-Val461 HEK293
LIL-HM2B1 LILRB1/CD85j/ILT2 Human No C-hFc Gly24-His458 HEK293
LIL-HM3B1 LILRB1/CD85j/ILT2 Human No C-mFc Gly24-His458 HEK293
LIL-HM4B1B LILRB1/CD85j/ILT2 Human Yes C-His-Avi Gly24-His458 HEK293
LIL-HM4B1 LILRB1/CD85j/ILT2 Human No C-His-Avi Gly24-His458 HEK293
LIL-CM1RB LILRB1/CD85j/ILT2 Cynomolgus No C-His Gly41-His474 HEK293
LIL-HM11D LILRB1/CD85j/ILT2 Domain1&2 Human No C-His Gly24-Gly221 HEK293
LIL-CM1B2 LILRB2/CD85d/ILT4 Cynomolgus No C-His Gly24-Arg457 HEK293
LIL-CM2B2 LILRB2/CD85d/ILT4 Cynomolgus No C-hFc Gly24-Arg457 HEK293
LIL-HM2B2 LILRB2/CD85d/ILT4 Human No C-hFc Gln22-His458 HEK293
LIL-HM3B2 LILRB2/CD85d/ILT4 Human No C-mFc Gln22-His458 HEK293
LIL-HM4B2 LILRB2/CD85d/ILT4 Human No C-His-Avi Gln22-His458 HEK293
LIL-HM4B2B LILRB2/CD85d/ILT4 Human Yes C-His-Avi Gln22-His458 HEK293
LIL-HM12D LILRB2/CD85d/ILT4 Domain1&2 Human No C-His Gln22-Val229 HEK293
LIL-HM4B3 LILRB3/CD85a/ILT5 Human No C-His-Avi Gly24-Glu443 HEK293
LIL-HM4B3B LILRB3/CD85a/ILT5 Human Yes C-His-Avi Gly24-Glu443 HEK293
LIL-CM1B4 LILRB4/CD85k/ILT3 Cynomolgus No C-His Gln22-Glu259 HEK293
LIL-HM2B4 LILRB4/CD85k/ILT3 Human No C-hFc Gln22-Arg256 HEK293
LIL-HM4B4 LILRB4/CD85k/ILT3 Human No C-His-Avi Gln22-His257 HEK293
LIL-HM4B4B LILRB4/CD85k/ILT3 Human Yes C-His-Avi Gln22-His257 HEK293
LIL-MM1B4 LILRB4/CD85k/ILT3 Mouse No C-His Gly24-Lys238 HEK293
LB4-HM1D1 LILRB4/CD85k/ILT3 Domain 1 Human No C-His-Avi Gln22-Thr118 HEK293
LB4-HM1D1B LILRB4/CD85k/ILT3 Domain 1 Human Yes C-His-Avi Gln22-Thr118 HEK293
LB4-HM4D4 LILRB4/CD85k/ILT3 Domain 1+hinge Human No C-His-Avi Gln22-Lys123 HEK293
LB4-HM4D4B LILRB4/CD85k/ILT3 Domain 1+hinge Human Yes C-His-Avi Gln22-Lys123 HEK293
LB4-HM1D3B LILRB4/CD85k/ILT3 Domain 2 Human Yes C-His-Avi Gly119-Glu259 HEK293
LIL-HM4B5 LILRB5/CD85c/LIR-8 Human No C-His-Avi Arg18-His456 HEK293
LIL-HM4B5B LILRB5/CD85c/LIR-8 Human Yes C-His-Avi Arg18-His456 HEK29

Obtain a physiologically relevant culture surface for pluripotent stem cell maintenance, expansion, and differentiation.

Research-Grade & Preclinical-Grade Laminin 521

Matrix protein for maintenance of pluripotent stem cells.

KACTUS has successfully developed a high-quality Laminin 521 product that can be applied to scientific research (research-grade) and preclinical development (preclinical-grade). It can effectively support the normal growth and passage of PSCs, maintain good stemness, and ensure the homogeneous growth of cells with genetic stability. Laminin 521 can be applied to the cultivation of stem cells and other primary cells and the development of related stem cell products.

Available Products

Parameter Research-Grade Preclinical-Grade
Catalog # LMN-HM521 LMN-HM522
Concentration 0.1mg/mL 0.1mg/mL
Purity ≥ 95% ≥ 95%
Endotoxin < 1EU/mL < 1EU/mL
TSE/BSE X Animal-Origin Free

Order Now

KACTUS Laminin 521 Features

Use on Various Cell Types

Applicable to a wide range of cells: iPSCs, hMSCs & most anchorage-dependent progenitor cell types

Expect Quality

> 95% Purity

Low Internal Toxicity (<10EU/mg)

Transition to Feeder-Free Culture

Compatible with a variety of feeder-free stem cell culture media

Maintain Growth

Maintain homogeneous growth and karyotype stability of stem cells

Recombinant Laminin for Stem Cell Culture

Due to their unique ability for self-renewal and directional differentiation, stem cells can be applied in many fields such as embryonic development research, drug screening modeling, and cell therapy. At the same time, stem cell culture methods continue to be optimized. Laminin 521 is an important matrix adhesion protein, which can recreate a suitable growth environment for primary cells such as stem cells, and is currently one of the most commonly used trophoblast-free culture substrates.

Figure 1. The main components of globular basement membrane (GBM) [2].

Laminin 521 can maintain the pluripotency of stem cells, promote cell proliferation, support the clonal expansion of pluripotent human stem cells and the growth of skin keratinocytes. It is also involved in the regulation of important physiological processes such as cell adhesion, migration, differentiation, phenotype maintenance, and matrix-mediated signal transduction [3]. Compared with Laminin 511, Laminin 521 can support the monolayer maintenance and expansion of stem cells in the absence of apoptosis inhibitors (such as ROCK inhibitors). It can be an excellent alternative to Laminin 511 and to some extent, is more suitable for human pluripotency stem cell culture than Laminin 511.

What are the applications of Laminin 521?

Stem Cell Expansion Culture

Laminin 521 can support the low-density growth and self-renewal of stem cells in a chemically defined, animal-free environment. It is suitable for the culture of hSC, iSC and cloned stem cells, such as hPSC [4], MSC, hematopoietic stem cells, etc.

Directed Differentiation of Stem Cells

Laminin 521 promotes the differentiation of hPSCs into different cell types such as hepatocytes, cardiomyocytes, retinal pigment epithelial (RPE) cells [5] and endothelial cells [6]. hESCs grown on Laminin 521 can exhibit molecular phenotypic characteristics of hepatocytes and undergo cell self-organization [7].

Organoid Culture

Indeterminate media replacing Matrigel is a major target for organoid culture, and full-length laminin (rather than laminin-derived peptides) has been shown to be a key component for the correct formation of organoids in gel models. Lucendo-Villarin and collaborators developed an economical automated platform for the generation of human hepatic spheroids from pluripotent stem cell-derived hepatic progenitors, endothelial cells, and hepatic stellate cells with the help of laminin 521, which can be used in disease modeling and drug screening research [8].

Growth Maintenance of Differentiated Primary Cells

Laminin 521 can support the growth and proliferation of differentiated primary cells, such as cardiomyocytes, retinal pigment epithelial (RPE) cells, nerve cells, endothelial cells, islet cells, etc. For example, the basement membrane damage of the isolated islets will cause islet function decline and cell death, but when cultured on a matrix containing Laminin 521, it can significantly promote the survival and function maintenance of islet cells [9], and has now been successfully applied in the original Generation islet cell culture system. Likewise, cardiac progenitor cells differentiated in vitro can proliferate on Laminin 521-containing matrices and transform into mature cardiomyocytes.

Drug Research

Laminin 521 is a new anti-GBM disease pulmonary hemorrhage autoantibody target. Studies have shown that in anti-glomerular basement membrane disease, circulating antibodies can recognize Laminin 521 in addition to type IV collagen, indicating that Laminin 521 is Another major autoantigen against GBM [10], autoantibodies against Laminin 521 may promote lung injury and lead to pulmonary hemorrhage by increasing the total amount of IgG bound to the alveolar basement membrane, which provides theoretical clues for the development of related drugs.

Maintain Expression of Stem Cell Markers & iPSC Growth In Vitro

KACTUS Laminin 521 was pre-coated with 0.5µg/cm² in a 6-well dish, seeding the thawed iPSC cells at a concentration of 1×10⁴/cm². After 5 days of culture, stem cell markers were detected via flow cytometry.

Figure 2. Normal expression of stem cell markers OCT3/4, SOX2, SSEA4, TRA-1-60, etc.:

Figure 3. Laminin 521 can effectively maintain the growth of human iPSCs.

What is Laminin 521?

Laminin 521 (LN521, LAMB2, LN-11) is a heterotrimeric glycoprotein composed of α5, β2 and γ1 chains, expressed in stem cells and most basement membranes (especially in the nerve sheath, muscle nerve junction and glomerular basement membrane GBM). It is a key matrix protein that supports the growth of stem cells and maintains the stability and performance of the basement membrane.

Laminin 521 can form a huge net-like material environment together with nestin, collagen, fibronectin, glycosaminoglycan, and other extracellular matrix components. It is a key supportor of various tissues such as muscle fiber, epithelium, nerve, capillaries, fat, etc. In addition, the LG1-5 region of Laminin 521 can bind to cell membrane surface integrin α6β1 or α3β1, etc., start the downstream PI3K-Akt signaling pathway, and promote cell proliferation.

Figure 4. Laminin 521 structure [1].

How do I use Laminin 521?

General recommended procedure:

1. Coat the cell culture flask/dish with Laminin 521 (a typical dosage is 0.5 μg/cm² but this can vary depending on the experiment).

2. Wash the cells and incubate with digestive enzymes or EDTA.

3. Separate into a single cell suspension, centrifuge, and resuspend in appropriate fresh medium.

4. Seed cells on culture flask/dish coated with Laminin 521.

References

[1] Pulido D, Briggs DC, Hua J, Hohenester E. Crystallographic analysis of the laminin β2 short arm reveals how the LF domain is inserted into a regular array of LE domains. Matrix Biol. 2017 Jan;57-58:204- 212.

[2] Naylor RW, Morais MRPT, Lennon R. Complexities of the glomerular basement membrane. Nat Rev Nephrol. 2021 Feb;17(2):112-127.

[3] Yap L, Tay HG, Nguyen MTX, Tjin MS, Tryggvason K. Laminins in Cellular Differentiation. Trends Cell Biol. 2019 Dec;29(12):987-1000.

[4] Dziedzicka D, Markouli C, Barbé L, Spits C, Sermon K, Geens M. A High Proliferation Rate is Critical for Reproducible and Standardized Embryoid Body Formation from Laminin-521-Based Human Pluripotent Stem Cell Cultures. Stem Cell Rev Rep . 2016 Dec;12(6):721-730.

[5] Lynch VJ, Nnamani MC, Kapusta A, Brayer K, Plaza SL, Mazur EC, Emera D, Sheikh SZ, Grützner F, Bauersachs S, Graf A, Young SL, Lieb JD, DeMayo FJ, Feschotte C, Wagner GP . Ancient transposable elements transformed the uterine regulatory landscape and transcriptome during the evolution of mammalian pregnancy. Cell Rep. 2015 Feb 3;10(4):551-61.

[6] Nguyen MTX, Okina E, Chai X, Tan KH, Hovatta O, Ghosh S, Tryggvason K. Differentiation of Human Embryonic Stem Cells to Endothelial Progenitor Cells on Laminins in Defined and Xeno-free Systems. Stem Cell Reports. 2016 Oct 11;7(4):802-816.

[7] Cameron K, Tan R, Schmidt-Heck W, Campos G, Lyall MJ, Wang Y, Lucendo-Villarin B, Szkolnicka D, Bates N, Kimber SJ, Hengstler JG, Godoy P, Forbes SJ, Hay DC. Laminins Drive the Differentiation and Self-Organization of hESC-Derived Hepatocytes. Stem Cell Reports. 2015 Dec 8;5(6):1250-1262.

[8] Meseguer-Ripolles J, Kasarinaite A, Lucendo-Villarin B, Hay DC. Protocol for automated production of human stem cell derived liver spheres. STAR Protoc. 2021 Apr 30;2(2):100502.

[9] Brandhorst D, Brandhorst H, Lee Layland S, Acreman S, Schenke-Layland K, Johnson PRV. Basement membrane proteins improve human islet survival in hypoxia: Implications for islet inflammation. Acta Biomater. 2022 Jan 1;137:92- 102.

[10] Shen CR, Jia XY, Luo W, Olaru F, Cui Z, Zhao MH, Borza DB. Laminin-521 is a Novel Target of Autoantibodies Associated with Lung Hemorrhage in Anti-GBM Disease. J Am Soc Nephrol. 2021 Aug ;32(8):1887-1897.

About CAR-T Therapy

Chimeric antigen receptor-modified T-cell (CAR-T) therapy is a novel immunotherapy approach that has achieved remarkable success in the treatment of a variety of hematological malignancies. The basis of CAR-T therapy is to make the immune system attack cancer cells. Briefly, patient T cells are isolated and genetically engineered to express a chimeric antigen receptor (CAR) that recognizes specific tumor-associated antigens (TAAs) such as CD19, a cell surface protein that is uniformly and strongly expressed on malignant B cells. Two new FDA-approved CD19-specific drugs, KymriahTM and YescartaTM, demonstrate the importance of TAAs in CAR-T cell therapy research.

Utilizing our SAMSTM platform, KACTUS has developed a series of recombinant proteins covering multiple CAR-T cell therapeutic targets, including difficult-to-express proteins such as CD19 and BCMA. We offer various types of highly active CAR-T target antigen proteins, including site-directed labeled proteins, fluorescent labeled proteins, biotin-labeled proteins, etc., which can flexibly meet different research and development needs such as CAR-T positive rate detection.

Performance Validation

Human FITC Compatible CD19

Figure 1. Use Human CD19-FITC Compatible protein to detect the expression rate of Anti-CD19-CAR positive cells. Non-transfected 293T cells and FITC-labeled protein control were used as negative control.

PE-Labeled Human EGFR VIII

Figure 2. 293T-CAR Cells were incubated with PE-Labeled Human EGFR VIII, His Tag and PE-labeled protein control. Non-transfected 293T cells and PE-labeled protein control were used as negative control.

Biotinylated Human MSLN

Figure 3. Anti-MSLN CAR-293T cells were incubated with Biotinylated human MSLN-hFc-Avi Tag. Non-transfected 293T cells and Fc-labeled protein control were used as negative control. SA-FITC was used to evaluate the binding activity of Biotinylated Human MSLN.

Catalog No. Description Product Tag Exact Sequence
ITG-HM461 Human Integrin alpha 6 beta 1 (ITGA6&ITGB1) Heterodimer Protein C-His-Avi Phe24-Gly1012 (ITGA6) acidic tail & GIn21-Asp728 (ITGB1) basic tail
ITG-MM4V3B Biotinylated Mouse Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein C-His-Avi Phe31-Val988(ITGAV)acidic tail & Glu26-Asp717(ITGB3)basic tail
ITG-HM18B Human Integrin alpha 8 beta 1 (ITGA8&ITGB1) -Heterodimer Protein C-His Phe39-Leu1012(ITGA8) acidic tail & Gln21-Asp728(ITGB1) basic tail
ITG-CM1V3 Cynomolgus Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein C-His Phe31-Pro993(ITGAV)acidic tail & Gly27-Asp718(ITGB3)basic tail
ITG-HM2V3 Human Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein C-hFc Phe31-Val992(ITGAV)acidic tail & Gly27-Asp718(ITGB3)basic tail
ITG-HM110 Human Integrin alpha 10 beta 1 (ITGA10&ITGB1) Heterodimer Protein C-His Phe23-Ser1122(ITGA10)acidic tail & Gln21-Asp728(ITGB1)basic tail
ITG-MM110 Mouse Integrin alpha 10 beta 1 (ITGA10&ITGB1) Heterodimer Protein C-His Phe23-Leu1119(ITGA10)acidic tail & Gln21-Asp728(ITGB1)basic tail
ITG-MM1V3 Mouse Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein C-His Phe31-Val988(ITGAV)acidic tail & Glu26-Asp717(ITGB3)basic tail
ITG-MM2V3 Mouse Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein C-hFc Phe31-Val988(ITGAV)acidic tail & Glu26-Asp717(ITGB3)basic tail
ITG-HM4V6B Biotinylated Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein C-His-Avi Phe31-Val992(ITGAV) acidic tail & Gly22-Asn707(ITGB6) basic tail
ITG-MM1A1 Mouse Integrin alpha 1 beta 1 (ITGA1&ITGB1) Heterodimer Protein C-His Phe29-Pro1141(ITGA1)acidic tail & Gln21-Asp728(ITGB1)basic tail
ITG-MM1LB Mouse Integrin alpha L beta 2 (ITGAL&ITGB2) Heterodimer Protein C-His Tyr24-His1087 (ITGAL) acidic tail & Gln24-Asn702 (ITGB2) basic tail
ITG-HM4V3B Biotinylated Human Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein C-His-Avi Phe31-Val992(ITGAV) acidic tail & Gly27-Asp718(ITGB3) basic tail
ITG-HM4V5B Biotinylated Human Integrin alpha V beta 5 (ITGAV&ITGB5) Heterodimer Protein C-His-Avi Phe31-Val992(ITGAV)acidic tail & Gly24-Asn719(ITGB5)basic tail
ITG-HM4V8B Biotinylated Human Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein C-His-Avi Phe31-Val992(ITGAV) acidic tail & Glu43-Arg684(ITGB8) basic tail
ITG-HM451B Biotinylated Human Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein C-His-Avi Phe42-Tyr995(ITGA5)acidic tail & Gln21-Asp728(ITGB1)basic tail
ITG-RM1V8 Rhesus macaque Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein C-His Phe31-Pro993(ITGAV) acidic tail & Glu43-Ser681(ITGB8) basic tail
ITG-RM1V6 Rhesus macaque Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein C-His Phe31-Pro993(ITGAV) acidic tail & Gly22-Asn707(ITGB6) basic tail
ITG-MM1V8 Mouse Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein C-His Phe31-Val988(ITGAV)acidic tail & Gly22-Ser679(ITGB8)basic tail
ITG-MM1V6 Mouse Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein C-His Phe31-Val988(ITGAV)acidic tail & Gly22-Asn706(ITGB6)basic tail
ITG-MM1AB Mouse Integrin alpha 2 beta 1 (ITGA2&ITGB1) Heterodimer Protein C-His Tyr27-Thr1129(ITGA2) acidic tail & Gln21-Asp728(ITGB1) basic tail
ITG-MM12B Mouse Integrin alpha 2B beta 3 (ITGA2B&ITGB3) Heterodimer Protein C-His Leu32-Arg988(ITGA2B) acidic tail & Glu26-Asp717(ITGB3) basic tail
ITG-HM4V8 Human Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein C-His-Avi Phe31-Val992(ITGAV) acidic tail & Glu43-Arg684(ITGB8) basic tail
ITG-HM4V5 Human Integrin alpha V beta 5 (ITGAV&ITGB5) Heterodimer Protein C-His-Avi Phe31-Val992(ITGAV)acidic tail & Gly24-Asn719(ITGB5)basic tail
ITG-HM4V6 Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein C-His-Avi Phe31-Val992(ITGAV) acidic tail & Gly22-Asn707(ITGB6) basic tail
ITG-HM4V3 Human Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein C-His-Avi Phe31-Val992(ITGAV)acidic tail & Gly27-Asp718(ITGB3)basic tail
ITG-HM451 Human Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein C-His-Avi Phe42-Tyr995(ITGA5) acidic tail & Gln21-Asp728(ITGB1) basic tail
ITG-HM1XB Human Integrin alpha X beta 2 (ITGAX&ITGB2) Heterodimer Protein C-His Phe20-Pro1107(ITGAX) acidic tail & Gln23-Asn700(ITGB2) basic tail
ITG-HM1AB Human Integrin alpha 2 beta 1 (ITGA2&ITGB1) Heterodimer Protein C-His Tyr30-T1132(ITGA2) acidic tail & Gln21-Asp728(ITGB1) basic tail
ITG-HM1A1 Human Integrin alpha 1 beta 1 (ITGA1&ITGB1) Heterodimer Protein C-His Phe29-Pro1141(ITGA1) acidic tail & Gln21-Asp728(ITGB1) basic tail
ITG-HM12B Human Integrin alpha 2B beta 3 (ITGA2B&ITGB3) Heterodimer Protein C-His Leu32-Arg993(ITGA2B) acidic tail & GLy27-Asp718(ITGB3) basic tail

Soluble TCR Expression & SPR Characterization Services

Service Features

Production of various formats of soluble TCRs, including scFv-TCR, TCR-His, etc.

TCR engineering to optimize soluble TCR expression based on TCR modeling

SPR analysis of soluble TCR & Peptide-Ready MHC/Peptide-MHC interactions

SPR Characterization Services to Combat TCRs with Low Binding Affinity

TCRs often have low binding affinity to Peptide-MHCs (pMHC) which makes characterization via ELISA difficult. Alternatively, SPR is well suited for characterizing TCRS with low binding affinity. In addition to soluble TCR expression, we also offer SPR analysis services for characterizing the binding between TCRs and Peptide-MHCs or Peptide-Ready MHCs.

TCR Binding with Peptide-Ready MHC & Peptide-MHC

(A)

(B)

(C)

FigureLigandAnalyteka (1/Ms)kd (1/s)KD (M)
AprMHC + FMNKFIYEIAFP specific TCR2020000.06583.26e-7
BAFP pMHCAFP specific TCR3760000.153.99e-7
CprMHC (no peptide)AFP specific TCR//No Binding

Figure 1. HLA-A*02:01 neoantigen loading efficiency in Peptide-Ready MHC loaded with FMNKFIYEI peptide (A), Peptide-MHC with FMNKFIYEI peptide (B), and MHC with no peptide (C).

Peptide-MHCs, Peptide-Ready MHCs, & Soluble TCR Expression

Get full support for your TCR therapy drug development endeavors with our comprehensive customized TCR and Peptide-MHC complex expression services.

Expression Validation: gp100 TCR & Anti-CD3 Bispecific Fusion Protein

Figure 2. We have successfully expressed Tebentafusp, which not only binds to the GP100 (HLA-A*02:01) complex but also simultaneously binds to CD3 heterodimers, demonstrating excellent bidirectional binding activity. In ELISA (left) and SPR (right) analyses, Tebentafusp can bind to both monomers and tetramers of Human GP100 (HLA-A*02:01) complex, with an EC50 and affinity constant of 11.8 ng/mL and 0.196 nM, respectively.

About TCR Therapy

What is TCR Therapy?

TCR therapy is a novel immunotherapy developed based on the recognition pattern between the body’s TCR and antigens. It includes two forms: T cell transfer therapy (TCR-T) and TCR protein drugs (TCR-scfv, TCR mimic antibodies, etc.). Among them, the principle of TCR-T involves first screening and validating TCR sequences that can recognize antigens. Through genetic engineering, these sequences are integrated into the patient’s T cells, equipping them with the ability to selectively bind to and eliminate tumor cells expressing the target antigens. In this context, “antigen” refers to complexes formed by MHC (or HLA) with intracellular antigen peptides. Through this unique recognition mechanism, TCR-T can target a wider range of intracellular antigens, leading to more pronounced effects in solid tumors.

Figure 3. TCR Recognition of MHC-Peptide Complex [2]

Figure 4. TCR-T Treatment Process [3]

Advantages of TCR Therapy

High specificity and sensitivity are prominent features of TCR-T therapy, especially in generating robust T cell responses against low-density antigen populations. Additionally, it exhibits a lower probability of cytokine release syndrome. Furthermore, compared to CAR, TCRs often possess lower affinity and faster dissociation, enabling continuous triggering of recognition responses and facilitating the amplification of immune signals.

CR-scfv & TCR Mimic Antibodies

TCR-scfv (single chain variable fragment) and TCR mimic antibodies represent a novel class of protein engineering techniques, focusing directly on the development of protein drugs using TCR or TCR-like structures. This approach eliminates the need for genetic engineering and T cell transfer, resulting in a simpler manufacturing process and providing a more streamlined treatment option for clinical use. A representative drug in this category is Tebentafusp, currently the only approved TCR therapy on the market. It can simultaneously recognize the GP100 peptide-(HLA*02:01) complex and CD3.

Figure 5. TCR-T Treatment Process [3]

References

[1] http://www.scgcell.com/

[2] Natarajan K, Jiang J, May NA, Mage MG, Boyd LF, McShan AC, Sgourakis NG, Bax A, Margulies DH. The Role of Molecular Flexibility in Antigen Presentation and T Cell Receptor-Mediated Signaling. Front Immunol. 2018 Jul 17;9:1657.

[3] Tsimberidou AM, Van Morris K, Vo HH, Eck S, Lin YF, Rivas JM, Andersson BS. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021 Jun 30;14(1):102.

[4] Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunol Rev. 2019 Jul;290(1):127-147.

References

[1] Fang KK, Lee JB, Zhang L. Adoptive Cell Therapy for T-Cell Malignancies. Cancers (Basel). 2022 Dec 23;15(1):94.

[2] Mangal JL, Handlos JL, Esrafili A, Inamdar S, Mcmillian S, Wankhede M, Gottardi R, Acharya AP. Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies. Cancers (Basel). 2021 Mar 5;13(5):1123.

[3] Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM, Dermime S. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023 Jan 30;22(1):20.

SUPPORT

outstanding technical support

PRODUCT

we offer a full product guarantee

DELIVERY

we offer free delivery to UK universities and non profit organisations